Evidence map›Paper›PMID 26592184›Full record

ArticleScientific reports2015

P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression.

Camila Guerra Martinez, Daniel Zamith-Miranda, Marcia Gracindo da Silva, Karla Consort Ribeiro, Izaíra Trincani Brandão, Celio Lopes Silva, Bruno Lourenço Diaz, Maria Bellio, Pedro Muanis Persechini, Eleonora Kurtenbach

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The ATP-dependent Pathways and Human Diseases.Current medicinal chemistry · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Regulatory Role of CD4Journal of immunology research · 2018
    Review
  11. Purinergic Signalling: Therapeutic Developments.Frontiers in pharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Camila Guerra MartinezInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brasil.
Daniel Zamith-MirandaInstituto de Microbiologia Prof. Paulo de Goes, Universidade Federal do Rio de Janeiro, 21941-900 Rio de Janeiro, RJ, Brasil.
Marcia Gracindo da SilvaInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brasil.
Karla Consort RibeiroInstituto Nacional de Propriedade Industrial. Rua São Bento no 1, Rio de Janeiro, RJ, 20090-010, Brazil.
Izaíra Trincani BrandãoDepartamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, Brasil.
Celio Lopes SilvaDepartamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, Brasil.
Bruno Lourenço DiazInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brasil.
Maria BellioInstituto de Microbiologia Prof. Paulo de Goes, Universidade Federal do Rio de Janeiro, 21941-900 Rio de Janeiro, RJ, Brasil.
Pedro Muanis PersechiniInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brasil.
Eleonora KurtenbachInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brasil.
Universidade Federal do Rio de Janeiro · BRUniversidade de Ribeirão Preto · BRFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro · BRInstituto Nacional da Propriedade Industrial · BRNational Council for Scientific and Technological Development · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoantibodies against the M2 receptors (M2AChR) have been associated with Dilated Cardiomyopathy (DCM). In the heart, P2×7 receptors influence electrical conduction, coronary circulation and response to ischemia. They can also trigger pro-inflammatory responses and the development of neurological, cardiac and renal disorders. Here, P2×7(-/-) mice displayed an increased heart rate and ST segment depression, but similar exercise performance when compared to wild type (WT) animals. After immunization with plasmid containing M2AChR cDNA sequence, WT mice produced anti-M2AChR antibodies, while P2×7(-/-) mice showed an attenuated production. Despite this, WT and P2×7(-/-) showed left ventricle cavity enlargement and decreased exercise tolerance. Transfer of serum from M2AChR WT immunized mice to näive recipients led to an alteration in heart shape. P2×7(-/-) mice displayed a significant increase in the frequency of spleen regulatory T cells population, which is mainly composed by the FoxP3(+)CD25(-) subset. M2AChR WT immunized mice showed an increase in IL-1β, IFNγ and IL-17 levels in the heart, while P2×7(-/-) group produced lower amounts of IL-1β and IL-17 and higher amounts of IFNγ. These results pointed to previously unnoticed roles of P2×7 in cardiovascular and immune systems, and underscored the participation of IL-17 and IFNγ in the progress of autoimmune DCM.

Indexed as

AnimalsAutoantibodiesAutoantigensCardiomyopathy, DilatedFemaleForkhead Transcription FactorsGene Expression RegulationHeart RateImmunizationInterferon-gammaInterleukin-17Interleukin-1betaInterleukin-2 Receptor alpha SubunitMiceMice, Inbred C57BLMice, KnockoutAutoantibodiesAutoantigensForkhead Transcription FactorsFoxp3 protein, mouseIl2ra protein, mouseInterferon-gammaInterleukin-17Interleukin-1betaInterleukin-2 Receptor alpha SubunitReceptor, Muscarinic M2Receptors, Purinergic P2X7

Identifiers

PMID26592184
PMCPMC4655336
OpenAlexW2396974083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.